Purchase Order 75N91020P00258

<p>The National Cancer Institute issued a purchase order to Acea Biosciences, Inc. on June 27, 2019 for maintenance agreement services with a ceiling value of $15,627.60 and an ultimate completion date of June 29, 2020. Place of performance is San Diego, California. The order was awarded under firm fixed price on a no-set-aside basis.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. valued at $4,275.00 on February 5, 2020, for a service agreement to de-obligate expiring FY20 lines. Work is performed at Bethesda, Maryland. The order carries firm fixed pricing and completed on February 28, 2021. No set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $15,480.00 on May 22, 2020, with completion scheduled for June 29, 2021. Work is performed in San Diego, California. The order is firm fixed price with no set-aside designation. Acea Biosciences is a subsidiary of Agilent Technologies and supplies life sciences instrumentation, software, consumables, and services to federal research organizations.</p>

The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $22,504.00 on March 1, 2018, with a completion date of August 31, 2018. The order is a firm fixed price, commercial acquisition with no small business set-aside. Performance takes place in Bethesda, Maryland. The procurement covers specialized life sciences equipment, instrumentation, or related services aligned with Acea's portfolio of flow cytometry, cell analysis, and biosensing products for research...

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for one year of extended service warranty coverage for a Novo Cyte Three laser system, valued at $11,958.00, with an award date of November 30, 2018. Place of performance is Bethesda, Maryland. The warranty period runs through November 29, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $15,627.60 on June 29, 2017, with completion by June 30, 2018. No set-aside applies. Work is performed in San Diego, California. The order covers life sciences instrumentation, software, services, consumables, and expertise related to flow cytometry and cell analysis technology, priced on a firm fixed price basis.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $32,593.00 on August 7, 2019, for in vitro testing of anti-cancer therapeutics using Xcelligence technology. Work is performed in San Diego, California. The order is firm fixed price with an ultimate completion date of September 6, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $2,916.59 on July 1, 2014, for preventative maintenance service on an Xcelligence DP invasion machine (Serial # 32-1110-1728-7). Performance is in Bethesda, Maryland, with completion by June 30, 2015. The order was placed under firm fixed-price terms with no small business set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for $48,544.00 on August 7, 2026, with an ultimate completion date of August 6, 2027. The order is firm fixed price with no set-aside applied. Work is performed in Carlsbad, California. The purchase order procures EVOS M7000 laboratory imaging equipment.</p>

<p>The National Cancer Institute awarded a purchase order to Molecular Devices LLC for $7,821.75 on March 14, 2019, with an ultimate completion date of March 14, 2020. The order is firm fixed price with no set-aside designation. Place of performance is Gaithersburg, Maryland. The purchase order was issued to de-obligate funds from FY2019 expiring lines in accordance with NIH Office of Administrative Law and Management communication.</p>